Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
- Status
- UNKNOWN
- Phase
- N/A
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- Status
- TERMINATED
- Phase
- PHASE1
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2